Researchers sent a survey to physicians who are part of the Infectious Diseases Society of America Emerging Infections Network in August 2022, asking about whether C. auris screening is conducted at their facility, the number of cases identified and other related questions, according to a CIDRAP report on the survey findings, which were published March 7 in Infection Control & Hospital Epidemiology.
Overall, 37% of the 253 respondents indicated screening was conducted at their facility. This percentage was higher (59%) in regions where the fungus is more frequently identified, which researchers labeled as tier 3 or 4. Among those who indicated their facilities did screen for the pathogen, 77% reported screening upon admission and 51% reported screening patients once they are already in the facility.
“Altogether, these findings suggest opportunities to increase adoption of C. auris screening across U.S. facilities, which might aid detection and prevent spread within and among facilities,” researchers said.
Health agencies consider C. auris among the pathogens that pose the greatest threat to public health because of its ability to spread quickly in healthcare settings and cause severe infections among immunocompromised people. The U.S. saw its first clinical case in 2016. Between 2020 and 2021, cases grew 95%. Read more about C. auris here.
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.